Are the PCSK9 inhibitors the panacea of atherosclerosis treatment?

Click to increase image sizeClick to decrease image size

Declaration of interest

TA Turner’s institution has received research support from Amgen and Sanofi for clinical trials and central laboratory analysis. EA Stein has received consulting fees from Amgen, Regeneron, Sanofi, Genentech, Roche, The Medicines Co, ISIS, Catabasis, AstraZeneca, CymaBay, CVS/Caremark and BMS related to PCSK9 inhibitors and other lipid lowering drugs. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Additional information

Funding

This paper was not funded.